July 04, 2018

Theratechnologies Submits Novel Single-Vial Formulation of EGRIFTA® (Tesamorelin for Injection) for FDA Approval

Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that it has filed a supplemental new drug application (sNDA) with the Food and Drug Administration (FDA) for a single-vial formulation of EGRIFTA®.